Open AccessCardioprotective effects of GLP‐1(28‐36a): A degraded metabolite or GLP‐1’s better half?
Author(s) -
Liu Yangyang,
Kubota Sodai,
Iizuka Katsumi,
Yabe Daisuke
Publication year - 2020
Publication title -
journal of diabetes investigation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.089
H-Index - 50
eISSN - 2040-1124
pISSN - 2040-1116
DOI - 10.1111/jdi.13302
Subject(s) - medicine , diabetes mellitus , medical school , family medicine , library science , gerontology , medical education , endocrinology , computer science
Molecular mechanism underlying glucagon‐like peptide‐1 exertion of cardioprotective effects in glucagon‐like peptide‐1 receptor‐dependent and ‐independent manners. Glucagon‐like peptide‐1 (28‐36a) enters coronary artery endothelial cells through macropinocytosis and binds to mitochondrial trifunctional protein‐α, shifting substrate utilization to increase adenosine triphosphate production and modulating a adenosine triphosphate‐sensor soluble adenylyl cyclase, thereby producing cyclic adenosine monophosphate and activating protein kinase A to exert cytoprotection from oxidative injury.